Device Trial Radar · NCT05486481
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 8, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Alfred Chung, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Janssen Pharmaceuticals; AbbVie
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial tests the safety, side effects, and best dose of venetoclax, daratumumab, and dexamethasone for the treatment of systemic light-chain amyloidosis in patients with a deoxyribonucleic acid (DNA) abnormality called a translocation involving chromosomes 11 and 14, or "t(11;14)". Venetoclax works by attaching to a protein called Bcl-2, in order to kill cancer cells. Daratumumab works by binding to a target on the surface of cancer cells called Cluster of differentiation 38 (CD38). When daratumumab binds to CD38, it enables the immune system to find the cancer cell and kill it. Dexamethasone is a type of drug called a corticosteroid. A corticosteroid is a drug made of artificial steroid hormones, that are used to treat symptoms such as inflammation (swelling and irritation to a part of the body). The combination of these medications may more effectively treat patients with systemic light-chain amyloidosis and t(11;14).
Conditions
- AL Amyloidosis
- Light Chain (AL) Amyloidosis
- Systemic Light Chain Disease
Interventions
VenetoclaxDrug
Given orally (PO)
DexamethasoneDrug
Given PO
DaratumumabDrug
Given Subcutaneously (SC)
Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assayDevice
Lab test
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with reported dose limiting toxicities (Phase 1)Time frame: Up to 1 cycle (1 cycle is equal to 28 days)
- Maximum tolerated dose (MTD) (Phase 1)Time frame: Up to 1 cycle (1 cycle is equal to 28 days)
- Recommended phase 2 dose (RP2D) (Phase1)Time frame: Up to 1 cycle (1 cycle is equal to 28 days)
1 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.